Onco-Innovations Extends Marketing Program

Rhea-AI Summary

Onco-Innovations (ONNVF) has extended its marketing engagement with MCS Market Communication Service GmbH for online marketing services. The extended services include campaign creation, marketing materials production, and research and analytics. The program will run until June 30, 2025, or until budget exhaustion. Onco-Innovations has paid EUR 500,000 for this extension. The services will be delivered through digital channels, including Google Ads and native advertising. No securities were issued as compensation for these services.

VANCOUVER, BC / ACCESS Newswire / May 26, 2025 / Onco-Innovations Limited (CBOE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H)(WKN:A3EKSZ) ("Onco" or the "Company") announces, further to its news release dated March 25, 2025, that it has extended the term of its engagement with MCS Market Communication Service GmbH (business address: Rheinpromenade 13, 40789 Monheim am Rhein, Nordrhein-Westfalen, Deutschland, email: info@mcsmarket.de; telephone: +491772481220; and website: www.mcsmarket.de) ("MCS") for the continued provision of a range of online marketing services, including campaign creation, production of marketing materials, as well as research and analytics (the "Services"). The Services are expected to run until June 30, or until budget exhaustion. The Company has paid MCS EUR 500,000 for the extended term. No securities have been provided to MCS or its principals as compensation. The Services will be executed via digital channels, including Google Ads and native advertising.

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.

ON BEHALF OF ONCO-INNOVATIONS LIMITED,

"Thomas O'Shaughnessy"
Chief Executive Officer

For more information, please contact:

Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com

Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

SOURCE: Onco-Innovations Limited

View the original press release on ACCESS Newswire

FAQ

How much did Onco-Innovations (ONNVF) pay for the marketing extension with MCS?

Onco-Innovations paid EUR 500,000 to MCS Market Communication Service GmbH for the extended marketing services term.

What services will MCS provide to Onco-Innovations (ONNVF)?

MCS will provide online marketing services including campaign creation, production of marketing materials, research and analytics through digital channels like Google Ads and native advertising.

When does Onco-Innovations' (ONNVF) extended marketing program end?

The extended marketing program will run until June 30, 2025, or until the budget is exhausted.

Were any securities issued to MCS as compensation for the marketing services?

No, no securities were provided to MCS or its principals as compensation for the marketing services.